The Journal of Clinical Psychiatry · 1996 · 44 citations · 0 references
MedicinePharmacologyPsychiatryNeuropharmacologyPsychopharmacologyPsychophysiologyAnxiety DisordersAnxiolytic PharmacologyAnxiolytic PharmacotherapyAnxiolytic TherapyPanic DisorderPsychostimulant PharmacologyAgoraphobia TreatmentPanic Disorder TreatmentPanic Disorder With AgoraphobiaPanic Disorder Without AgoraphobiaPanic ProvocationPanic ReactionsPharmacological Anxiety ManagementTreatment Of Anxiety Disorders
BACKGROUND: The authors investigated whether 6 weeks of treatment with fluvoxamine would decrease the anxiogenic response to the 35% CO2 challenge in 11 patients with DSM-III-R panic disorder with agoraphobia. METHOD: The patients underwent a 35% CO2 challenge at baseline and again after 6 weeks of fluvoxamine treatment. RESULTS: The anxiogenic effect of CO2 was significantly (p < .05) reduced during fluvoxamine treatment. CONCLUSION: The results suggest a relationship between the anxiogenic effect of CO2 and the therapeutic effect of fluvoxamine.